Medical student Palak Patel remembers her mother’s mastectomy as she assists on an operation for a patient with breast cancer.
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
Next generation cancer diagnostics are poised to change the way that cancer is detected and treated. Ph.D. candidate Roshan Chikarmane shares his perspectives on the teams and technologies that are leading the charge.
The development and commercialization of cancer immunotherapies, a class of treatments that fights cancer by fortifying the immune system, has advanced at a rapid pace. Prior to 2017, most cancer immunotherapies were composed of antibodies that selectively flag cancer cells for destruction by other cells in the immune system. In mid-2017, the FDA approved Kymriah […]
As a callow biochemistry student, I often grappled with the onerous task of memorizing metabolic pathways. Gradually, however, I came to appreciate the underlying simplicity: Complex macromolecules are broken down to the same simple molecule. Metabolism is the workhorse of the cell — efficiently mining nutrients for energy, shunting surplus nutrients to build cellular structures, […]
While the word cancer treatment may identify everything from chemotherapy to radiation, there is significant variance between the type of cancer and its responsiveness to even the most promising therapies. That has been precisely the case for the α-PD-1 immunotherapy treatment. While it has shown remarkable efficacy in patients diagnosed with lung cancer, other types […]
What do an anti-parasitic drug used to treat pinworms and a frequently used anti-malarial drug have in common? According to recent studies from the labs of Johns Hopkins and University of Kentucky investigators, both mebendazole and chloroquine could be promising medicines to combat cancer. Mebendazole has been in use as an anti-helminthic drug since 1971. […]
Parkinson’s disease is a neurodegenerative condition caused by the death of dopamine-producing cells in a region of the brain called the substantia nigra, which leads to disruptions in neural circuits controlling motor function. Although the cause of this inappropriate cell death is largely unclear, one hypothesis is that it is due to the abnormal aggregation […]